BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988-997. [PMID: 27726239 DOI: 10.1002/jmri.25486] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 de Laforcade L, Bobot M, Bellin MF, Clément O, Grangé S, Grenier N, Wynckel A, Guerrot D. Kidney and contrast media: Common viewpoint of the French Nephrology societies (SFNDT, FIRN, CJN) and the French Radiological Society (SFR) following ESUR guidelines. Diagn Interv Imaging 2021;102:131-9. [PMID: 33531265 DOI: 10.1016/j.diii.2021.01.007] [Reference Citation Analysis]
2 Colafati GS, Rossi E, Carducci C, Piga S, Voicu IP, Mastronuzzi A, Tomà P. Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease. Pediatr Radiol 2018;48:1724-35. [PMID: 30046901 DOI: 10.1007/s00247-018-4204-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
4 Lancelot E, Raynaud J, Desché P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol 2020;55:578-88. [DOI: 10.1097/rli.0000000000000684] [Cited by in Crossref: 10] [Article Influence: 10.0] [Reference Citation Analysis]
5 Braun J, Busse R, Darmon-Kern E, Heine O, Auer J, Meyl T, Maurer M, Hamm B, de Bucourt M. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients. Acta Radiol 2020;61:910-20. [PMID: 31739672 DOI: 10.1177/0284185119883390] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Djelouah M, Marical V, Kanagaratnam L, Kianmanesh R, Biron A, Cadiot G, Hoeffel C. Diagnosis of postoperative recurrence of Crohn disease with MR-enterography: Value of diffusion-weighted imaging. Diagn Interv Imaging 2021:S2211-5684(21)00145-5. [PMID: 34154981 DOI: 10.1016/j.diii.2021.06.002] [Reference Citation Analysis]
7 Jornet D, Soyer P, Terris B, Hoeffel C, Oudjit A, Legmann P, Gaujoux S, Barret M, Dohan A. MR imaging features of pancreatic acinar cell carcinoma. Diagn Interv Imaging. 2019;100:427-435. [PMID: 30846400 DOI: 10.1016/j.diii.2019.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Martí-bonmatí L, Martí-bonmatí E. Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias. Radiología 2017;59:469-77. [DOI: 10.1016/j.rx.2017.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Cho SB, Lee AL, Chang HW, Kim KA, Yoo WJ, Yeom JA, Rho MH, Kim SJ, Lim YJ, Han M. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. J Magn Reson Imaging 2020;51:861-8. [PMID: 31663202 DOI: 10.1002/jmri.26940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:223-30. [PMID: 31816007 DOI: 10.1001/jamainternmed.2019.5284] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 62.0] [Reference Citation Analysis]
12 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
13 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
14 Jakobsen JÅ, Quattrocchi CC, Müller FHH, Outteryck O, Alcázar A, Reith W, Fraga P, Panebianco V, Sampedro A, Pietura R. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study. BMC Med Imaging 2021;21:74. [PMID: 33879075 DOI: 10.1186/s12880-021-00600-9] [Reference Citation Analysis]
15 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
16 Granata V, Fusco R, Avallone A, Cassata A, Palaia R, Delrio P, Grassi R, Tatangelo F, Grazzini G, Izzo F, Petrillo A. Abbreviated MRI protocol for colorectal liver metastases: How the radiologist could work in pre surgical setting. PLoS One 2020;15:e0241431. [PMID: 33211702 DOI: 10.1371/journal.pone.0241431] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Endrikat J, Dohanish S, Schleyer N, Schwenke S, Agarwal S, Balzer T. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. Invest Radiol 2018;53:541-50. [PMID: 29547493 DOI: 10.1097/RLI.0000000000000462] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 11.5] [Reference Citation Analysis]
18 Tsushima Y, Awai K, Shinoda G, Miyoshi H, Chosa M, Sunaya T, Endrikat J. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol 2018;36:676-85. [PMID: 30232584 DOI: 10.1007/s11604-018-0778-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
19 Wong MCY, Piaggio G, Damasio MB, Molinelli C, Ferretti SM, Pistorio A, Ghiggeri G, Degl'Innocenti ML, Canepa A, Incarbone V, Mattioli G. Hydronephrosis and crossing vessels in children: Optimization of diagnostic-therapeutic pathway and analysis of color Doppler ultrasound and magnetic resonance urography diagnostic accuracy. J Pediatr Urol 2018;14:68.e1-6. [PMID: 29133170 DOI: 10.1016/j.jpurol.2017.09.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Forbes-amrhein MM, Dillman JR, Trout AT, Koch BL, Dickerson JM, Giordano RM, Towbin AJ. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children. Invest Radiol 2018;53:313-8. [DOI: 10.1097/rli.0000000000000444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
21 Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, Hill MD, James MT, Kirpalani A, Lydell CP, Roifman I, Sarak B, Sterns LD, Verma A, Wan D, Crean AM, Grosse-Wortmann L, Hanneman K, Leipsic J, Manlucu J, Nguyen ET, Sandhu RK, Villemaire C, Wald RM, Windram J; Primary Panel., Secondary Panel. 2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Can J Cardiol 2021;37:835-47. [PMID: 34154798 DOI: 10.1016/j.cjca.2021.02.012] [Reference Citation Analysis]
22 McWilliams RG, Frabizzio JV, De Backer AI, Grinberg A, Maes BD, Zobel BB, Gottschalk A. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. J Magn Reson Imaging 2020;51:607-14. [PMID: 31287213 DOI: 10.1002/jmri.26851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
23 Taton B, De La Faille R, Asselineau J, Perez P, Merville P, Colin T, Combe C, Sourbron S, Grenier N. A prospective comparison of dynamic contrast-enhanced MRI and 51Cr-EDTA clearance for glomerular filtration rate measurement in 42 kidney transplant recipients. European Journal of Radiology 2019;117:209-15. [DOI: 10.1016/j.ejrad.2019.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Barat M, Hoeffel C, Bouquot M, Jannot AS, Dautry R, Boudiaf M, Pautrat K, Kaci R, Camus M, Eveno C, Pocard M, Soyer P, Dohan A. Preoperative evaluation of small bowel complications in Crohn’s disease: comparison of diffusion-weighted and contrast-enhanced MR imaging. Eur Radiol 2019;29:2034-44. [DOI: 10.1007/s00330-018-5734-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]